Chemed (CHE) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| UBS | Initiated Coverage | Buy | $650.00 | Sep 25, 2026 |
| Oppenheimer | Maintained | Outperform | $590.00 from $500.00 | Jul 31, 2026 |
| RBC Capital | Maintained | Sector Perform | $548.00 from $436.00 | Jul 30, 2026 |
| B of A Securities | Maintained | Neutral | $510.00 from $450.00 | Jul 9, 2026 |
| RBC Capital | Maintained | Sector Perform | $436.00 from $422.00 | Apr 27, 2026 |
| Oppenheimer | Maintained | Outperform | $500.00 from $580.00 | Feb 27, 2026 |
| RBC Capital | Downgraded | Outperform → Sector Perform | $422.00 from $572.00 | Feb 27, 2026 |
| Jefferies | Downgraded | Buy → Hold | $475.00 from $550.00 | Jan 22, 2026 |
| RBC Capital | Maintained | Outperform | $572.00 from $589.00 | Nov 10, 2025 |
| B of A Securities | Maintained | Buy | $595.00 from $610.00 | Sep 10, 2025 |
| Jefferies | Upgraded | Hold → Buy | $550.00 from $490.00 | Sep 2, 2025 |
| Oppenheimer | Maintained | Outperform | $580.00 from $650.00 | Jul 31, 2025 |
| RBC Capital | Maintained | Outperform | $589.00 from $640.00 | Jul 31, 2025 |
| Jefferies | Initiated Coverage | Hold | $500.00 | Jul 25, 2025 |
| B of A Securities | Maintained | Buy | $650.00 from $708.00 | Jun 30, 2025 |
| RBC Capital | Maintained | Outperform | $640.00 from $674.00 | Jun 30, 2025 |
| RBC Capital | Maintained | Outperform | $674.00 from $667.00 | Apr 28, 2025 |
| RBC Capital | Maintained | Outperform | $667.00 from $633.00 | Mar 14, 2025 |
| RBC Capital | Maintained | Outperform | $633.00 from $697.00 | Nov 5, 2024 |
| RBC Capital | Maintained | Outperform | $697.00 from $712.00 | May 21, 2024 |
Frequently asked questions
What is the price target for CHE stock?
The average 12-month analyst price target for Chemed (CHE) is $596.00, with a high estimate of $650.00 and a low of $548.00, across 3 analysts.
Is CHE a buy, sell, or hold?
Analysts covering Chemed currently average a Hold rating: 2 buy, 3 hold and 1 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for CHE?
The average price target of $596.00 implies 16.14% upside from the last price of $513.18.
What is the latest analyst rating on CHE?
On Sep 25, 2026, UBS initiated coverage of Chemed at Buy with a price target of $650.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.